FISCAL YEAR 2023, STRATEGIC TRANSFORMATION OF THE GROUP
- Continued total year growth in core business revenues, up 39%
- Successful deployment of the Group's strategy:
- Proprietary products up at 30% of revenues
- Internationalization, with 38% of revenues now generated outside of
France
- Acquisition of DID in
Italy effective as ofJuly 1 st, 2023 - Acquisition of Alpha Biotech, GenDx distributor, effective as of
January 3 rd, 2024
Strong growth of core business at +39%
In 2022, the Group generated sales of €152.6 million. Excluding non-recurring sales from the COVID business (€59.1m), growth for 2023 therefore reached +39%.
On a comparable proforma basis, i.e. excluding perimeter effects linked to acquisitions and non-recurring items, growth of the core business remained dynamic, at +12%.
in €m | H1 2022 | 2023 | change. / core | at constant scope | |||||
TOTAL | COVID | core | |||||||
Revenues | 152.6 | 59.1 | 93.5 | 130.1 | +39% | +12% | |||
unaudited |
Successful deployment of the Group's strategy
The Group is successfully pursuing its strategy of targeted geographic and technological expansion, with the ambition of becoming a major international company in the specialty diagnostics market, providing its customers with a comprehensive molecular diagnostics offering, including its own solutions and those of its partners.
- Share of proprietary products at 30% of revenues
The share of proprietary products represents 30% of revenues (compared to 18% of core revenues in 2022), thanks in particular to the contribution of GenDx, consolidated in the Group's financial statements as of
- Continued international expansion
International sales represents 38% of 2023 revenues (against 25% of core business revenues in 2022). This increase is mainly due to the new acquisitions made over the past year in
Integration and international strategy continues in 2024 with the acquisition of the
Outlook
With the confirmation of the strategic priorities chosen over the last few years, the
Next financial meeting
2023 annual results :
About For more information, please visit: www.eurobio-scientific.com The company is publicly listed on the Euronext Growth market in Euronext Growth BPI Innovation, PEA-PME 150 and Next Biotech indices, Euronext European Rising Tech label. Symbol: ALERS - ISIN Code: FR0013240934 - Reuters: ALERS.PA - Bloomberg: ALERS:FP |
Contacts |
Tel. +33(0) 1 69 79 64 80 | Calyptus Investors Relations Tel. +33(1) 53 65 68 68 - eurobio-scientific@calyptus.net |
Attachment
- 20240130_PR_EurobioScientific_CA_TY_23_EN
© OMX, source